ABSTRACT
At present,most chemotherapy schemes for malignant tumors use the standard chemotherapy regimen recommen-ded by the National Comprehensive Cancer Network(NCCN)clinical practice guidelines,because they ignore the inherent heterogenei-ty of the tumor,resulting in low efficiency,high toxic and side effects,and high costs issues. Therefore,the realization of " individual-ized and accurate medical care" for cancer is a general trend. The sensitivity screening of chemotherapy drugs for cancer patients to a-chieve individualized precise drug delivery is one of the main contents of "individualized precision medicine". The three-dimensional histoculture drug response assay( HDRA) is a method for detecting drug sensitivity after in vitro cultivation of active tumor tissue blocks obtained by surgical resection or biopsy. It not only has a short experimental cycle,but it also maintains the tumor tissue struc-ture,heterogeneity and micro-environment,which have high clinical practice consistency,and it is a relatively promising technique for detecting drug susceptibility. Therefore,this article reviews the development history,clinical application and the future development trend of HDRA.
